The use of the synthetic drugs has increased in the last few decades; however, these drugs exhibit various side effects. Scientists are therefore seeking alternatives from natural sources. Commiphora gileadensis has long been used to treat various disorders. It is commonly known as bisham or balm of Makkah. This plant contains various phytochemicals, including polyphenols and flavonoids, with biological potential. We found that steam-distilled essential oil of C. gileadensis exhibited higher antioxidant activity (IC_50, 22.2 µg/mL) than ascorbic acid (IC_50, 1.25 µg/mL). The major constituents (>2%) in the essential oil were β-myrcene, nonane, verticiol, β-phellandrene, β-cadinene, terpinen-4-ol, β-eudesmol, α-pinene, cis-β-copaene and verticillol, which might be responsible for the antioxidant and antimicrobial activity against Gram-positive bacteria. The extract of C. gileadensis exhibited inhibitory activity against cyclooxygenase (IC_50, 450.1 µg/mL), xanthine oxidase (251.2 µg/mL) and protein denaturation (110.5 µg/mL) compared to standard treatments, making it a viable treatment from a natural plant source. LC-MS analysis revealed the presence of phenolic compounds such as caffeic acid phenyl ester, hesperetin, hesperidin, chrysin and transient amounts of catechin, gallic acid, rutin and caffeic acid. The chemical constituents of this plant can be explored further to investigate its wide variety of therapeutic potential.

Background: The rise in antimicrobial resistance has necessitated the exploration of novel antimicrobial agents. Zinc oxide nanoparticles (ZnO-NPs) have gained prominence due to their biocompatibility, minimal toxicity, and potent antimicrobial properties. This study evaluates the antimicrobial activity of ZnO-NPs synthesized from Phoenix dactylifera root extract and their potential applications in disinfection. Methodology: ZnO-NPs were synthesized using an eco-friendly method involving Phoenix dactylifera root extract and zinc acetate at varied concentrations and ratios, followed by annealing. The nanoparticles were characterized and assessed for antimicrobial activity against a spectrum of bacterial and fungal isolates using microtiter broth dilution, disc diffusion, and pour plate assays. Disinfection efficacy was evaluated on water samples and surfaces. Additionally, the impact of ZnO-NPs on acid-fast bacilli (AFB) isolates was examined using VersaTrek Mycobottles. Results: ZnO-NPs exhibited potent antimicrobial activity against Gram-positive and Gram-negative bacteria, with minimum inhibitory concentrations (MICs) ranging from 9.7 to 310 µg/mL. Disc diffusion assays revealed larger inhibition zones in Gram-positive bacteria compared to Gram-negative strains, with MRSA showing the widest zone (24 mm). ZnO-NPs significantly reduced colony-forming units (CFU) on water and surfaces, achieving complete bacterial inhibition on laboratory benches within 20 minutes. The nanoparticles demonstrated bactericidal effects against AFB isolates, highlighting their broad-spectrum efficacy. Conclusion: The study underscores the potential of ZnO-NPs as a versatile antimicrobial agent effective against MDR (multidrug-resistant) pathogens and environmental contaminants. Their rapid action and broad-spectrum activity make them suitable for disinfection in clinical and environmental settings. Future research could explore synergistic combinations with traditional antimicrobials to enhance efficacy against infections that are resistant to treatment.

Glioblastoma multiforme continues to be one of the most aggressive brain cancers, posing a serious health challenge, as it offers a median survival of only 15–23 months and a 5-year survival rate of less than 6%. Current treatments often prove inadequate, underscoring the urgency for new therapeutic strategies. This study investigated the potential of silencing the PFKFB4 and HMOX1 genes in U87-MG glioblastoma cells using small interfering RNAs (siRNAs), both alone and alongside the chemotherapeutic agents temozolomide (TMZ) and doxorubicin (DOX). Through MTT assays, qPCR, and wound healing techniques, we assessed cell viability, gene expression, and cell migration. Notably, siPFKFB4 enhanced DOX’s cytotoxic effect, reducing its IC₅₀ by six-fold, while having a milder impact with TMZ. When both siRNAs were combined with DOX, the IC₅₀ decreased by two-fold without harming normal cells. Although siHMOX1 reduced cell migration, it only modestly affected cell proliferation with either DOX or TMZ. The gene expression analysis demonstrated that the siPFKFB4/DOX treatment led to an upregulation of pro-apoptotic genes such as DPYSL4, while simultaneously downregulating anti-apoptotic genes, including BCL-2 and PARP2. In contrast, the siHMOX1 combination influenced the expression of 14 genes, significantly enhancing the levels of CYLD, FAS, and CASP3, which are key promoters of apoptosis. In migration assays, siPFKFB4/DOX and siHMOX1/DOX reduced cell migration by 65 and 75%, respectively. These findings suggest that siPFKFB4 combined with DOX offers a promising pathway for GBM therapy, advocating further exploration into effective central nervous system drug delivery methods.

COVID-19 vaccines were developed at an unprecedented speed in history. The factors affecting the response to COVID-19 vaccines are not clear. Herein, the effects of vitamin D and vitamin A (retinol) levels on the response to the BNT162b2 vaccine were explored. A total of 124 vaccine recipients were recruited from the general population attending vaccination centers in Irbid, Jordan. Blood samples were collected immediately before receiving the first vaccine dose (D0) and three weeks later (D21). Baseline (D0) levels of 25-hydroxyvitamin D [25(OH)D], retinol, and SARS-CoV-2 S1 IgG antibodies were measured with ELISA. The response to the BNT162b2 vaccine was tested by measuring the levels and avidity of SARS-CoV-2 S1 IgG antibodies on D21. The participants were divided into two groups, unexposed and exposed, based on the D0 SARS-CoV-2 antibody results. No significant correlation was found between the levels of 25(OH)D or retinol and the levels, avidity, or fold increase of antibodies in both groups. Similarly, no significant difference in antibody response was found between 25(OH)D status groups, retinol status groups, or combined status groups. These findings show that the baseline vitamin D or vitamin A levels have no effect on the short-term response to a single dose of BNT162b2 vaccine.

β-Glucans, naturally occurring β-D-glucose polysaccharides from fungi, yeast, bacteria, algae, and cereals, have emerged as promising immunomodulatory agents in antiviral defense. Their structural diversity—encompassing β-1,3, β-1,6, and β-1,4 linkages—underpins varied solubility, bioavailability, and biological activity, driving their therapeutic potential. Unlike conventional antivirals that target viral replication, β-glucans enhance host immunity by activating innate and adaptive responses through receptors such as dectin-1, toll-like receptors, and complement receptor 3, thereby stimulating macrophages, neutrophils, and natural killer cells to produce antiviral cytokines (e.g., interferons, interleukins) and induce trained immunity for long-term protection. This review explores β-glucans’s mechanisms in combating viral infections, including SARS-CoV-2, HPV, HBV, influenza, and HIV, highlighting direct antiviral effects (e.g., inhibiting viral entry via sulfated derivatives), immune modulation (e.g., enhancing T-cell responses and antibody production), and inflammation control (e.g., mitigating cytokine storms). Preclinical and clinical evidence underscores their ability to reduce viral load, enhance vaccine efficacy, and support tissue repair, as seen in HPV-related lesions. β-Glucans also modulate the gut microbiota, bolstering mucosal immunity. Despite promising outcomes, challenges like structural heterogeneity and limited large-scale trials persist. This article outlines the therapeutic prospects of β-glucans, emphasizing their potential as safe and versatile adjuncts to address emerging viral threats and enhance global health resilience.

Acinetobacter baumannii is a troublesome bacterium that is highly prevalent in hospital settings, particularly in intensive care units (ICUs). Biofilm is one of the main virulence factors that makes A. baumannii a successful pathogen, enabling it to survive the harshest environments. This study aimed to corrolate the biofilm‐forming capacity of clinical A. baumannii isolates with their antibiotic resistance phenotypes and isolation sources. A total of 327 clinical isolates originated from different hospitals, were recovered from diverse clinical specimens collected from patients admitted to the ICU and non‐ICU wards. The isolates were characterized for their resistance phenotypes and biofilm formation capacities. Most A. baumannii isolates showed high resistance patterns against all examined antibiotics. Based on the resistance profiles, 81.2% and 12.3% of isolates were classified into extensively resistant (XDR) and multidrug‐resistant (MDR), respectively. Moreover, the number of the ICU isolates exhibiting the XDR phenotype (86.7%) was higher than non‐ICU XDR isolates (76.4%). The biofilm‐forming capacity varied among the isolates, with most of the isolates forming either strong (44.3%) or weak biofilms (25.7%). Additionally, the fraction of ICU isolates with a strong capacity to form biofilms (60.7%, 91/150) was higher compared with the non‐ICU isolates (30.5%, 54/177). We found a significantly higher tendency to form biofilms in isolates that are susceptible to 10 out of the 17 antibiotics ( p = 0.014–0.002), including three carbapenems. In addition, a significant difference in the ability to form biofilms was revealed between the isolates originating from different hospitals and clinical specimens. Notably, a higher tendency to form biofilms was associated with susceptible strains isolated from blood ( p = 0.024–0.04) and cerebrospinal fluid ( p = 0.001–0.009). Our findings indicate that investigating the biofilm formation capacity of clinical A. baumannii strains could help identify patients requiring short or extended therapeutic treatments.